TRANS-NET consists of 12 Partners from 11 EU states including 1 partner from a Newly Associated State. The consortium scientific/clinical teams are all experts in clinical and or experimental allogeneic HSCT. Their expertise is multidisciplinary and includes immunopathology, immunology, molecular biology, dermatology, haematology, cell biology and bioinformatics.  Expert research teams with expertise in predictive bioassays, predictive genomics, tools for early diagnostics and novel therapeutics who will train and teach researchers in the key technologies of, for example, mRNA expression profiling, skin explant pathology.

TRANS-NET will form the first network of scientists and clinicians across Europe to develop a forum for the use of genomic and biological predictive and diagnostic markers in HSCT. The consortium will develop an information database of predictive indicators and diagnostic markers together with a library search of all relevant information and standardised consortium laboratory protocols.

The scientific team includes experts in molecular biology including pharmacogenomics, HLA and non-HLA immunogenetics and experimental animal models. The consortium equally has experts in immunobiology, biochemistry and in vitro and in vivo model systems including animal models of transplantation and gene expression profiling.

The clinical teams include transplant physicians specialising in paediatric as well as adult disease. All are members of the European Bone Marrow Transplant (EBMT) group. Several are also members of the International Bone Marrow Transplant Registry (IBMTR) and are on Advisory and or Regulatory Boards concerned with ethics and or safety of bone marrow transplants not only for the welfare of the patients but also for that of the donors. Professor Greinix for example is on the World Marrow Donor Association (WMDA). The consortium includes clinicians renowned world-wide for their pioneering work in HSCT. Professor Kolb for the use of donor lymphocyte infusion (DLI) for the cure of relapse disease; Prof. Holler for the role of cytokines in clinical GvHD and Prof. Greinix for the use of extracorporeal photopheresis (ECP) in the treatment of GvHD. The teams in Newcastle, Regensburg and Munich are building ECP treatment regimens in collaboration with colleagues in Vienna. Clinical teams also join scientific partners as collaborators for the collection and exchange of samples and clinical data. The clinical team will form their own Clinical Committee Chaired by Professor Holler which will include clinical partners and collaborators and make decisions on the importance of the project results to clinical medicine.

All of the clinical partners are involved in the laboratory scientific research. The clinical teams are therefore naturally integrated into the laboratory research and results discussed within partners' laboratories as well as at General Assemblies and Executive and Clinical Committee meetings.

A PDF version of the HUMAN RESOURCES AND MOBILITY (HRM) ACTIVITY is available here